ADMA
Price
$18.01
Change
+$0.70 (+4.04%)
Updated
Jul 25 closing price
Capitalization
4.3B
9 days until earnings call
RYTM
Price
$86.45
Change
-$0.82 (-0.94%)
Updated
Jul 25 closing price
Capitalization
5.7B
8 days until earnings call
Interact to see
Advertisement

ADMA vs RYTM

Header iconADMA vs RYTM Comparison
Open Charts ADMA vs RYTMBanner chart's image
ADMA Biologics
Price$18.01
Change+$0.70 (+4.04%)
Volume$3.28M
Capitalization4.3B
Rhythm Pharmaceuticals
Price$86.45
Change-$0.82 (-0.94%)
Volume$402.79K
Capitalization5.7B
ADMA vs RYTM Comparison Chart in %
Loading...
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. RYTM commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a StrongBuy and RYTM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ADMA: $18.01 vs. RYTM: $86.45)
Brand notoriety: ADMA and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 115% vs. RYTM: 54%
Market capitalization -- ADMA: $4.3B vs. RYTM: $5.7B
ADMA [@Biotechnology] is valued at $4.3B. RYTM’s [@Biotechnology] market capitalization is $5.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, ADMA is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 5 TA indicator(s) are bullish while RYTM’s TA Score has 5 bullish TA indicator(s).

  • ADMA’s TA Score: 5 bullish, 3 bearish.
  • RYTM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ADMA is a better buy in the short-term than RYTM.

Price Growth

ADMA (@Biotechnology) experienced а +7.65% price change this week, while RYTM (@Biotechnology) price change was -3.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ADMA is expected to report earnings on Aug 06, 2025.

RYTM is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($5.71B) has a higher market cap than ADMA($4.3B). RYTM YTD gains are higher at: 54.430 vs. ADMA (5.015). ADMA has higher annual earnings (EBITDA): 161M vs. RYTM (-145.8M). RYTM has more cash in the bank: 314M vs. ADMA (71.6M). RYTM has less debt than ADMA: RYTM (4.06M) vs ADMA (82M). ADMA has higher revenues than RYTM: ADMA (459M) vs RYTM (137M).
ADMARYTMADMA / RYTM
Capitalization4.3B5.71B75%
EBITDA161M-145.8M-110%
Gain YTD5.01554.4309%
P/E Ratio21.44N/A-
Revenue459M137M335%
Total Cash71.6M314M23%
Total Debt82M4.06M2,018%
FUNDAMENTALS RATINGS
ADMA vs RYTM: Fundamental Ratings
ADMA
RYTM
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
2023
SMR RATING
1..100
15100
PRICE GROWTH RATING
1..100
5437
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADMA's Valuation (74) in the Biotechnology industry is in the same range as RYTM (98). This means that ADMA’s stock grew similarly to RYTM’s over the last 12 months.

ADMA's Profit vs Risk Rating (20) in the Biotechnology industry is in the same range as RYTM (23). This means that ADMA’s stock grew similarly to RYTM’s over the last 12 months.

ADMA's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for RYTM (100). This means that ADMA’s stock grew significantly faster than RYTM’s over the last 12 months.

RYTM's Price Growth Rating (37) in the Biotechnology industry is in the same range as ADMA (54). This means that RYTM’s stock grew similarly to ADMA’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADMA (100). This means that RYTM’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMARYTM
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
76%
Momentum
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
75%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STLYX38.610.13
+0.34%
SEI Tax-Managed Large Cap Y (SIMT)
ANCFX89.940.28
+0.31%
American Funds Fundamental Invs A
LICAX17.56N/A
N/A
Lord Abbett International Equity A
IIIIX13.23-0.01
-0.08%
Voya International Index Port I
BLRYX11.65-0.01
-0.09%
Brookfield Global Listed Real Estate I

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with TARS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then TARS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+4.04%
TARS - ADMA
42%
Loosely correlated
-2.21%
IMTX - ADMA
41%
Loosely correlated
+1.71%
ACLX - ADMA
39%
Loosely correlated
+1.48%
RYTM - ADMA
39%
Loosely correlated
-0.94%
KRYS - ADMA
37%
Loosely correlated
-1.59%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with CRNX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-0.94%
CRNX - RYTM
46%
Loosely correlated
+1.91%
VRNA - RYTM
45%
Loosely correlated
+0.29%
RVMD - RYTM
43%
Loosely correlated
N/A
NRIX - RYTM
42%
Loosely correlated
-0.09%
IDYA - RYTM
42%
Loosely correlated
-1.33%
More